Lianhua Wei

Dr. Lianhua Wei


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2019 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
FQFamei Qi
Famei Qi
AZAihua Zhou
Aihua Zhou
LYLi Yan
Li Yan
XYXiumei Yuan
Xiumei Yuan
DWDanni Wang
Danni Wang
XZXu Zhang
Xu Zhang
Background: Early diagnosis decreases the mortality of hepatocellular carcinoma (HCC). We aimed to investigate the usefulness of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in the diagnosis of primary and metastatic HCC. Methods: One hundred and twenty patients with primary HCC (PHC), 115 with metastatic HCC (MHC), 89 with chronic liver disease (CLD), and 116 healthy volunteers were included. The diagnostic values of each marker and their combinations for HCC diagnosis were represented by ROC curve analyses. Results: PIVKA‐II, AFP, and AFP‐L3 levels in PHC group were higher than that in normal control, CLD, and MHC groups. CEA levels in MHC group were higher than that in the other three groups. When the four markers were analyzed individually, PIVKA‐II showed the highest positive rate in PHC group (76.7%) and CEA showed the highest positive rate in MHC group (69.6%). PIVKA‐ II showed the largest area under ROC curve (AUC = 0.835) to discriminate PHC group from CLD group. Combined PIVKA‐II with AFP‐L3 increased the AUC to 0.910. CEA showed the highest AUC (0.849) to discriminate MHC group from CLD group. Combined CEA with PIVKA‐II increased the AUC to 0.866. AFP‐L3 alone showed the highest AUC (0.890) to discriminate MHC group from PHC group. Combined PIVKA‐II with AFP‐L3, and CEA increased the AUC to 0.957. Conclusion: PIVKA‐II, AFP‐L3, AFP, and CEA are effective biomarkers for the diagnosis of PHC and MHC. Their combinations could improve the diagnostic performance compared with each marker used alone in detecting PHC and MHC.

29 May 2025 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
ZLZhangping Lu
Zhangping Lu
XLXiaofang Liang
Xiaofang Liang
WDWenbo Deng
Wenbo Deng
QLQianqian Liu
Qianqian Liu
YWYulin Wang
Yulin Wang
LWLianhua Wei
Lianhua Wei
Background: Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to the public health system due to its multi-drug resistance and strong biofilm-forming ability. Here, we explored the possible inhibitory mechanism of an antimicrobial peptide, Mastoparan X, against MRSAMethods: Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of Mastoparan X against MRSA USA300 were determined by microbroth dilution method. The antibacterial activity of Mastoparan X against USA300 was then evaluated by time-growth curves, membrane fluidity, reactive oxygen species(ROS), flow cytometry, scanning electron microscopy (SEM) and confocal laser scanning microscopy (CLSM). In addition, the inhibitory and scavenging effects of Mastoparan X on USA300 biofilm were evaluated using crystal violet staining. Finally, gene expression changes in USA300 after treatment with Mastoparan X were analyzed by transcriptomics and verified by RT-qPCR.Results: The MIC and MBC of Mastoparan X on USA300 were 32 μg/mL and 64 μg/mL, respectively. SEM observation showed significant changes in cell morphology after Mastoparan X treatment. Flow cytometry confirmed that Mastoparan X promoted the apoptosis of MRSA cells. In addition, Mastoparan X inhibited the formation of MRSA biofilm while destroying the mature bioepithelia already formed. Transcriptomic analysis showed that 851 genes were significantly altered and ABC transport protein, amino acid biosynthesis, glycolysis and tricarboxylic acid (TCA) cycle were inhibited after 16μg/mL Mastoparan X treatment.Conclusion: Our study demonstrated that Mastoparan X has potent bactericidal activity against MRSA and is expected to provide new potential peptides for the clinical treatment of MRSA.

1 October 2024 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
ZLZhihong Liu
Zhihong Liu
XLXiaofang Liang
Xiaofang Liang
YZYu Zhang
Yu Zhang
WDWenbo Deng
Wenbo Deng
YWYulin Wang
Yulin Wang
LWLianhua Wei
Lianhua Wei
The development of antibiotic resistance complicates the treatment of infectious diseases and is a global public health threat. However, drug repurposing can address this resistance issue and reduce research and development costs. Niclosamide is a salicylanilide compound approved by the Food and Drug Administration (FDA), and it has been used clinically for treating parasitic infections for many years. Recent studies have shown that niclosamide can inhibit bacterial and fungus activity by affecting the quorum sensing system, biofilm formation, cell membrane potential, and other mechanisms. Here, we discuss recent advances in the antimicrobial applications of niclosamide and its derivatives to provide new perspectives in treating infectious diseases.

28 November 2024 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
XLXiaofang Liang
Xiaofang Liang
ZLZhihong Liu
Zhihong Liu
YWYulin Wang
Yulin Wang
YZYu Zhang
Yu Zhang
WDWenbo Deng
Wenbo Deng
LWLianhua Wei
Lianhua Wei
Antimicrobial resistance is among the greatest threats to public health globally, and drug repurposing strategies may be advantageous to addressing this problem. Mefloquine, a drug traditionally used to treat malaria, has emerged as a promising antibiotic adjuvant, due to its ability to enhance the effectiveness of conventional antibiotics against resistant bacterial strains. In this paper, we first outline the enhancement properties of mefloquine and its mechanisms of action as an adjuvant antibiotic against multidrug-resistant bacteria. Mefloquine exhibits synergistic bacteriostatic effects when combined with colistin, β-lactams, antituberculosis drugs, quinolones, and linezolid. Potential mechanisms underlying its synergistic effects include inhibition of antibiotic efflux, disruption of bacterial cell membrane integrity, and disturbance of biofilm formation. In addition, we explore the bacteriostatic effects of several mefloquine derivatives against Mycobacterium tuberculosis and some fungi. Further, we summarize the findings of recent studies on other aspects of mefloquine activity, including its antiviral and antitumor effects. Finally, the advantages and challenges of mefloquine use as an antibiotic adjuvant in combination with antibiotics for bacterial inhibition are discussed. Overall, mefloquine shows excellent potential as an antibiotic adjuvant therapy against multidrug-resistant bacteria and is a promising candidate for combination therapy; however, further studies are needed to fully elucidate its mechanism of action and address the challenges associated with its clinical application.

14 January 2023 in International Journal of Analytical Chemistry
Verified
Journal Article
Open access
PDF file
YHYuandan He
Yuandan He
QLQianqian Liu
Qianqian Liu
LWLianhua Wei
Lianhua Wei
ZSZhipeng Sun
Zhipeng Sun
WLWenjuan Li
Wenjuan Li
HZHongwei Zhang
Hongwei Zhang
Background. Early diagnosis of sepsis is the key to timely, targeted treatment. Cell population data (CPD) has been widely used in many diseases, but its predictive value for early diagnosis and the clinical outcome of sepsis remains unclear. Therefore, this paper discusses whether peripheral blood leukocyte parameters can be used as predictive indicators for early diagnosis and the clinical outcome of sepsis. Methods. A retrospective study of 45 patients with sepsis, 53 patients with nonseptic infections, and 86 healthy check-ups admitted to Gansu Provincial Hospital from January 2021 to June 2022 was done using a hematology analyzer. Results. The results of LYMPH#, HFLC#, IG#, NE-WX, LY-WX, LY-WY, and MO-WX showed better diagnostic efficiency in the sepsis group and nonseptic infection group. When the seven differential leukocyte parameters were used to establish diagnostic models, the sensitivity and specificity were 82.20% and 77.40%, respectively. Correlation analysis showed that LYMPH# and HFLC# were positively correlated with PCT ( ). The clinical outcome of sepsis showed that the leukocyte parameters of discharged WBC and LY-X had better predictive efficacy. When the two differential leukocyte parameters were used to establish diagnostic models, the sensitivity and specificity were 90.90% and 100.00%. Cox regression analysis showed that leukocyte parameters of discharged WBC and LY-X were independent predictors of clinical outcomes ( ). Conclusion. Leucocyte parameters HFLC#, IG#, NE-WX, LY-WX, LY-WY, and MO-WX had a certain auxiliary effect on the early diagnosis of sepsis leukocyte parameters of discharged WBC and LY-X were independent predictors of clinical outcomes in patients with sepsis. Therefore, peripheral blood leukocyte parameters may have predictive value for early diagnosis and the clinical outcome of sepsis, but large-scale retrospective studies are still needed to prove our preliminary results.

22 January 2025 in Biomarkers in Medicine
Verified
Journal Article
Closed access
FLFugui Lin
Fugui Lin
LYLi Yan
Li Yan
XYXiumei Yuan
Xiumei Yuan
XYXingwen Yang
Xingwen Yang
XYXiaoyan Yang
Xiaoyan Yang
DLDehong Li
Dehong Li
Raftlin (raft-linking) protein is an essential component of the lipid raft structure and plays a crucial role in B and T cell signaling pathways. It facilitates B cell receptor (BCR) signaling by promoting calcium mobilization and tyrosine phosphorylation in the cells while colocalizing with BCR on the cell membrane. Interestingly, Raftlin is internalized in lipopolysaccharide-stimulated T cells by colocalization with Toll-like receptor 4 (TLR4), wherein it exerts a similar role as in B cells. The protein also effectuates poly(I:C) internalization into TLR3-positive endosomes in dendritic and epithelial cells through clathrin binding, thereby affecting interferon-β production. In addition, Raftlin controls the vascular endothelial cells and participates in cell growth and proliferation. Recent studies have indicated Raftlin to be a novel biomarker for the diagnosis due to its upregulated expression in malignant diseases. In this integrated study, we present the biological functions of Raftlin and its expression to provide a theoretical basis for the prevention, diagnosis, and treatment of various diseases.